Implantation of the clinical-grade human neural stem cell line, CTX0E03, rescues the behavioral and pathological deficits in the quinolinic acid-lesioned rodent model of Huntington’s disease

Yongwoo Yoon1 | Hyun Sook Kim2 | Iksoo Jeon1 | Jeong-Eun Noh1 | Hyun Jung Park1 | Suji Lee1 | In-Hyun Park3 | Lara Stevanato4 | Caroline Hicks4 | Randolph Corteling4 | Roger A. Barker5 | John D. Sinden4 | Jihwan Song1,6

1Department of Biomedical Science, CHA Stem Cell Institute, CHA University, Seongnam-si, Gyeonggi-do, Republic of Korea
2Department of Neurology, CHA Bundang Medical Center, CHA University, Seongnam-si, Gyeonggi-do, Republic of Korea
3Department of Genetics, Yale Stem Cell Center, Yale School of Medicine, New Haven, Connecticut
4ReNeuron, Pencoed Business Park, Bridgend, UK
5John van Geest Cambridge Centre for Brain Repair, Department of Clinical Neuroscience, University of Cambridge, Cambridge, UK
6iPS Bio, Inc., Seongnam-si, Gyeonggi-do, Republic of Korea

Correspondence
Jihwan Song, DPhil, CHA Stem Cell Institute, Department of Biomedical Science, CHA University, Rm 604, CHA Bio Complex, 335 Pangyo-ro, Bundang-gu, Seongnam-si, Gyeonggi-do 13488, Republic of Korea.
Email: jsong5873@gmail.com

Funding information
National Research Foundation of Korea, Grant/Award Number: NRF-2017M3A9B4061407; ips Bio, Inc; ReNeuron, United Kingdom

Abstract
Huntington’s disease (HD) is a devastating, autosomal-dominant neurodegenerative disease, for which there are currently no disease-modifying therapies. Clinical trials to replace the damaged striatal medium spiny neurons (MSNs) have been attempted in the past two decades but have met with only limited success. In this study, we investigated whether a clonal, conditionally immortalized neural stem cell line (CTX0E03), which has already shown safety and signals of efficacy in chronic ischemic stroke patients, could rescue deficits seen in an animal model of HD. After CTX0E03 transplantation into the quinolinic acid-lesioned rat model of HD, behavioral changes were measured using the rotarod, stepping, and staircase tests. In vivo differentiation and neuronal connections of the transplanted CTX0E03 cells were evaluated with immunohistochemical staining and retrograde tracing with Fluoro-Gold. We found that transplantation of CTX0E03 gave rise to a significant behavioral improvement compared with the sham- or fibroblast-transplanted group. Transplanted CTX0E03 formed MSNs (DARPP-32) and GABAergic neurons (GABA, GAD65/67) with BDNF expression in the striatum, while cortically transplanted cells formed Tbr1-positive neurons. Using a retrograde label, we also found stable engraftment and connection of the transplanted cells with host brain tissues. CTX0E03 transplantation also reduced glial scar formation and inflammation, as well as increasing endogenous neurogenesis and angiogenesis. Overall, our results demonstrate that CTX0E03, a clinical-grade neural stem cell line, is effective for preclinical test in HD, and, therefore, will be useful for clinical development in the treatment of HD patients.

KEYWORDS
CTX0E03, functional recovery, Good Manufacturing Practices (GMP), human neural stem cells, Huntington’s disease, intracerebral transplantation

Yongwoo Yoon and Hyun Sook Kim contributed equally to this study.
INTRODUCTION

Huntington’s disease (HD) is a devastating genetic disease, affecting approximately 5 out of every 100,000 people in the United States, Europe, and Australia. In HD, one of the earliest and major pathologies is the degeneration of the medium spiny neurons (MSNs) in the striatum due to the cytotoxic effects of mutant huntingtin protein. Coupled with pathology at other sites, especially the cortex, MSN degeneration leads to the classical clinical trial of abnormal movements, psychiatric problems, and cognitive deficits. Currently, there is no cure or disease-modifying therapy available for HD patients. Therefore, stem cells have long been considered a promising therapeutic resource for HD to replace the lost striatal MSNs as well as to modulate several pathogenic pathways through paracrine release of a range of neuroprotective and immune modulatory factors. A significant number of stem/progenitor cells have been studied that include embryonic stem cells; multipotent progenitor cells from the embryo or fetus, which are already partially committed to a neural lineage; cells from the umbilical blood; autologous or allogenic adult stem cells from various tissues; and finally induced pluripotent stem cells. Among them, neural stem cells (NSCs) have been regarded as a promising option to treat HD as they can survive and differentiate into proper neuronal cell types in vivo. Numerous studies have indicated that NSC can have the potential to replace the damaged MSNs and make functionally active connections to the host neuronal network. Both systemic injection of human NSC in the quinolinic acid (QA) rat model and intrastriatal injection of human NSC in the 3-NP rat model demonstrated reduced striatal damage and improved locomotor activity. Transplanted mouse NSC from neurons could survive in R6/2 transgenic HD model. More recently, intrastriatal transplantation of mouse induced pluripotent stem cell-derived NSCs (iPSC-NSC) in YAC128 mice also ameliorated locomotor deficits and differentiated into MSNs. Although various preclinical studies using different types of NSC in different rodent HD models have indicated its potential therapeutic benefits, no one has tested the efficacy of clinical-grade human NSC, such as CTX cells so far. Clinical trials of intracerebral transplantation using human fetal striatal tissues have demonstrated limited benefits and survival.

A sustainable source of ethically approved, safe, and potent stem cells is one of the most important requirements for the development of an effective cell therapy, and this holds for HD as well. CTX0E03 (CTX) is a GMP-manufactured conditionally immortalized human NSC line under current clinical trial (PISCES III, NCT03629275) with a viability of 96%. CTX cells were cultured in a serum-free medium (RMM) supplemented with 10% fetal bovine serum (Invitrogen) and 1% penicillin/streptomycin (Sigma-Aldrich) and maintained in Dulbecco’s modified Eagle’s medium (DMEM) high glucose (Welgene, Korea), supplemented with 10% fetal bovine serum (Invitrogen) and 1% penicillin/streptomycin (Sigma-Aldrich) grown on 0.2% gelatin-coated culture dish. For the transplantation of fibroblasts, they were dissociated using 0.25% trypsin-EDTA and resuspended at 100,000 cells/μL in DMEM human high glucose with 30 μM Y-27632 (Tocris) following centrifugation at 1200 rpm for 3 minutes.

MATERIALS AND METHODS

Cell preparation

Control fibroblast cell line

Embryonic fibroblasts were obtained from aborted human embryos following approval by the Institutional Review Board of CHA Gangnam Medical Center (Seoul, Korea). Fibroblasts were maintained in Dulbecco’s modified Eagle’s medium (DMEM) high glucose (Welgene, Korea), supplemented with 10% fetal bovine serum (Invitrogen) and 1% penicillin/streptomycin (Sigma-Aldrich) grown on 0.2% gelatin-coated culture dish. For the transplantation of fibroblasts, they were dissociated using 0.25% trypsin-EDTA and resuspended at 100,000 cells/μL in DMEM human high glucose with 30 μM Y-27632 (Tocris) following centrifugation at 1200 rpm for 3 minutes.

CTX (CTX0E03) drug product

CTX is of human origin and was established as a clonal cell line by conditional immortalization with c-mycER®. CTX0E03/06T passage 23 was revived from cryopreservation with a viability of 96%. CTX cells were cultured in a serum-free medium (RMM)
supplemented with epidermal growth factor (EGF, 20 ng/mL, Peprotech), basic fibroblast growth factor (bFGF, 10 ng/mL, Peprotech), and 4-hydroxytamoxifen (4-OHT, 10 mM, Sigma) on laminin (20 μg/mL, or 2.28 μg/cm² AMS Biotech) coated vessels in an incubator at 37°C in a humidified atmosphere containing 5% CO₂. The cells were fed every 2 to 3 days and passaged once the cells were 70% to 80% confluent. CTX drug product (DP) cells was prepared from two T-500 flasks, seeded and grown to 85% confluency for harvest at passage 32. For cell harvest, the medium was aspirated and the adherent cells washed with HBSS (–Ca²⁺/Mg²⁺). Cells were then dissociated with TrypZean/EDTA (BE02-034E Lonza) for 5 minutes before the addition of the DTI/Benzonase inhibitor (Invitrogen R007100; Merck 1.01654.0001). Cells were collected from flasks with 20 mL of RMM+GF+4-OHT and centrifuged at 500g (eg, 1500 rpm) for 5 minutes at ambient temperature. The cell pellet was resuspended in RMM+GF for trypan blue viability and cell counting, then centrifuged and resuspended in 57.7% HTS (HypoThermosal)-FRS/DMEM: F12 at a density of 50,000 cells/μL in HTS-FRS (BioLife Solutions, 101102). Finally, CTX (CTX0E03/DP (CTX0E03/07 passage 32) was prepared at ReNeuron (Guildford, UK) and shipped frozen under controlled conditions to the CHA Stem Cell Institute (Republic of Korea). For use, a vial of CTX0E03 cells was removed from −135°C storage and thawed immediately in a water bath at 37 (±1)°C for 1 minute before placing on ice for a maximum of 4 hours. Before each use, cells were gently triturated using a pipette. As for the medium control, HTS-FRS was used.

2.2 | QA model of HD and CTX cell transplantation

Animal experiments were performed in accordance with the CHA University Institutional Animal Care and Use Committee (IACUC140013). Male Sprague Dawley rats (Orient Bio Ltd, Seongnam, Korea) were group housed (12:12, light:dark cycle) and fed ad libitum. At 8 weeks of age, 50 rats received a single, unilateral injection of 2 μL volume containing 120 nmoL QA (2,3-pyridinedicarboxylic acid, Sigma) into the right striatum-stereotaxic coordinates AP = +1.0, ML = +2.5 mm, DV = −5.0 mm. One week after QA lesioning, animals that developed behavioral deficits in the rotarod (the time spent on the rotarod <60 seconds), stepping (the left step numbers <1), and staircase (the number of pellets taken <4) tests were selected for cell transplantation. A total of 32 QA-lesioned rats underwent stereotaxic injection into the striatum and the cortex with each site receiving 1 μL of the “transplant material” which contained either Media (N = 11, Sham group), 1 x 10⁵/μL Human Fibroblasts (N = 9), or 1 x 10⁵/μL CTX cells (N = 12). These cells were delivered at the coordinates, AP = +1.5, ML = +2.5 mm, DV = −5.0 mm for the striatum and AP = −0.5, ML = +1.5 mm, DV = −2.0 mm for the cortex. All animals received immunosuppressant, Cyclosporine A, by the intraperitoneal route starting at a dose of 10 mg/kg, 2 days prior to the transplantation surgery and then 5 mg/kg daily after surgery until sacrifice (Supporting Information Figure S1).

2.3 | Retrograde labeling with Fluoro-Gold

At 12 weeks post-transplantation, two rats from the CTX-transplanted group were injected with 0.5 μL volume of 4% Fluoro-Gold (FG) into the globus pallidus using the stereotaxic coordinates AP = −1.0, ML = +2.5 mm, DV = −6.0 mm. Animals were sacrificed 1 week after FG injection and processed for immunohistochemistry.

2.4 | BrdU administration

At 12 weeks post-transplantation, three rats from each of the Sham (Media), Fibroblast, and CTX-transplanted groups were injected with BrdU (Cat no B5002, Sigma-Aldrich) at a dose of 50 mg/kg twice daily, for 3 days by the intraperitoneal route. After 3 days of BrdU administration, animals were sacrificed and processed for immunohistochemistry.

2.5 | Behavioral testing

2.5.1 | Rotarod test

The rotarod test was performed at 0 (baseline), 2, 4, 6, 8, 10, and 12 weeks post-transplantation to assess motor coordination. Baseline was set before cell transplantation, which was performed 7 days after QA lesioning. Rats were placed on the rotating rod with an accelerating speed of 4 to 40 rpm over a period of 3 minutes with a 15 minutes rest period between trials. The time taken for each rat to fall from the rod was recorded over three separate trials and the mean latencies were used for analysis. Rats underwent rotarod test training comprising of three trials per day over three consecutive days prior to QA lesioning. Rats spent on the rotating rod for less than 60 seconds were selected for cell transplantation.

2.5.2 | Stepping test

The stepping test was performed at 0 (baseline), 2, 4, 6, 8, 10, and 12 weeks post-transplantation to assess akinesia. Rats were held on a tabletop in a forelimb stance, with their body at nearly 90° on the table. Once the rats appear relaxed, they were pushed forward to move along the surface of the tabletop. We counted the number of forepaw placements was counted as the rat was moved slowly in both forehand and backhand directions along the edge of a table
over a distance of 90 cm in a 5-second period. Rats used the left step more than one time were not selected for cell transplantation.

### 2.6.2 | CTX cell survival

Cell survival was evaluated with seven free-floating sections from each of the 12 CTX injected brains. A human-specific nuclei (hNu) antibody (1:200, MAB1281, Chemicon) was used with conventional single label DAB (3,3'-diaminobenzidine) immunohistochemistry to detect CTX cells.

### 2.6.3 | CTX cell differentiation

CTX differentiation was analyzed from the transplanted rat brains. Dual label fluorescence immunohistochemistry was performed using antibodies to the human-specific nuclei (1:200, MAB1281, Chemicon) or human-specific mitochondria (hMito; 1:200, AB3598, Chemicon) to detect CTX cells, combined with differentiation markers of DARPP-32 (1:100, #2306, Cell Signalling) for MSNs, GABA (1:1000, A2052, Sigma) and GAD 65/67 (1:200, AB1511, Chemicon) for GABAergic neurons, Tbr1 (1:200, ab31940, Abcam) and BDNF (1:200, Ab1534, Chemicon) for cortical neurons. Goat antimumous IgG-conjugated Alexa 555 (1:200, Molecular Probes) and goat antirabbit IgG-conjugated Alexa 488 (1:200, Molecular Probes) were used as secondary antibodies for detection and visualization, and a DAPI counterstain was applied. Images were captured using a confocal laser-scanning microscope imaging system (Leica TCS SP8, Germany).

### 2.6.4 | Host brain responses

Host brain responses were investigated on the transplanted rat brains. Based on the DAB immunohistochemistry, CTX-implanted animals showing a good graft survival with average behavioral scores were chosen (N = 3). As for the other experimental groups, three independent animals with average scores were chosen from the Sham (media, N = 3) and Fibroblast (N = 3) groups. Three independent sections from each animal (i.e., a total of nine sections from three brains of each experimental group) were used for immunohistochemical (IHC) analysis per each marker. Fluorescence immunohistochemistry was performed on free-floating sections using primary antibodies to investigate the glial scar with GFAP IHC (1:200, 556327, BD Biosciences), the microglial response with Iba-1 (1:100, 019-19741, Wako), the macrophage response with ED1 (1:100, MCA1957GA, Serotec), the inflammatory M1 macrophage phenotype with iNOS (1:100, sc-650, Santa Cruz), the anti-inflammatory M2 phenotype with CD206 (1:100, sc-34577, Santa Cruz), neurogenesis with DCX (1:200, #4604, Cell Signalling) and BrdU (1:100, 555 627 BD Pharmingen), and angiogenesis with Reca-1 (1:200, ab9774, Abcam). Goat antimumous IgG-conjugated Alexa 555 (1:200, Molecular Probes) and goat antirabbit IgG-conjugated Alexa 488 (1:200, Molecular Probes) were used as secondary antibodies, and a DAPI counterstain was applied. Images were captured using a confocal laser-scanning microscope imaging system (Leica TCS SP8). For BrdU immunohistochemistry, tissue sections underwent pretreatment in 0.1 M sodium citrate buffer for 30 minutes at 100 °C before incubation with the antibody. Host responses were quantified using the ImageJ software (NIH). Manual counts were used for collection (ED1, INOS, CD206 positive cells for macrophage responses; DCX, BrdU-positive cells for neurogenesis,
and Reca-1 positive blood vessels for angiogenesis) or measurement of the area of staining (GFAP for glial scar and Reca-1 for angiogenesis) within three separate 100 μm² regions of interest. For the glial scar, the region of interests (ROIs) of macrophage response and angiogenesis were sampled within the striatum and for neurogenesis, and the same ROIs were applied to each brain within the subventricular zone (SVZ). Data (counts or area) were statistically analyzed using the one-way analysis of variance (SigmaPlot).

3 | RESULTS

3.1 | Behavioral improvement following transplantation of CTX cells

To evaluate the therapeutic effect of CTX cells on animal model, we transplanted them into QA-lesioned rodent model of HD (N = 12). We used media (N = 11, Sham group) and human fibroblasts (N = 9, Fibroblast group) as control groups. On the rotarod, stepping and staircase tests, the CTX treated group exhibited significantly improved performance compared with Sham and Fibroblast only grafted groups, between 8- and 12-weeks post-transplantation (Figure 1).

3.2 | Survival, distribution, and differentiation of CTX cells in QA-lesioned brain

To prevent or reduce immune rejection of human-derived CTX cells when transplanted into a rat HD model, immunosuppressant, Cyclosporine A, was administered intraperitoneally, starting at a dose of 10 mg/kg, 2 days prior to the transplantation surgery and then 5 mg/kg daily after surgery until sacrifice. To determine whether CTX cells were integrated into the QA-lesioned host brain following transplantation, we performed histological analysis. Serial sections collected from the 12 CTX-implanted brains, in the range of AP: +1.6 mm and −1.2 mm, were subject to brightfield immunohistochemistry using a human-specific nuclei antibody (hNu) to detect surviving CTX cells (Figure 2). We detected CTX cells in the transplanted brains at 13 weeks postimplantation that were mostly located close to the site of transplantation, in the range of AP: +0.8 mm and −0.8 mm, in the lesioned striatum (Figure 2) as well as in the overlying cortex. Quantification of CTX survival in the striatum showed that over 10% of the original number of transplanted cells were present at 13 weeks post-transplantation. Sections from CTX-transplanted brains were also subject to double-label fluorescence immunohistochemistry to determine the level of neural differentiation within the graft. To identify the CTX-derived cells in the transplanted animals, we further performed immunohistochemistry with a series of antibodies against DARPP-32 (MSN), GABA and GAD 65/67 (GABAergic), BDNF and Tbr1 (glutamatergic). Microscopic analysis revealed that some surviving CTX cells in the lesioned striatum expressed markers specific for striatal neuronal subtypes, such as DARPP-32, GABA, and GAD 65/67 (Figure 3). In addition, some CTX cells in the striatum expressed the neurotrophic factor, BDNF (Figure 2). Only CTX cells transplanted into the cortex expressed Tbr1, a marker specific for cortical glutamatergic neurons (Figure 4).
3.3 | Neuronal connection between transplanted CTX cells and FG+ host brain cells

Microscopic analysis revealed that CTX cells in the striatum showed uptake of FG, which had been injected into the globus pallidus (Figure 4), indicating that CTX cells have established striatal-pallidal connections.

3.4 | Reduction of gliosis and host immune responses following transplantation of CTX cells

First, we investigated glial scar formation. Brain sections of three representative animals from each experimental group were subject to GFAP immunohistochemistry to demonstrate glial scar formation. GFAP staining, quantified by image analysis in the lesioned striatum,

**FIGURE 2** CTX cells can survive and differentiate into striatal neurons in the striatum of quinolinic acid (QA)-lesioned brain 13 weeks after transplantation. A, Widespread distribution of survived CTX cells were detected using a human nuclei antibody (hNu) and visualized with DAB (3,3′-diaminobenzidine) in the QA-lesioned striatum. Scale bar = 50 μm. B-E, Neuronal differentiation of CTX cells transplanted into the striatum (arrows) was identified by hNu colocalized with neuronal markers, including DARPP-32 (B), GABA (C), GAD 65/67 (D), and BDNF (E). Scale bar = 50 μm
was shown to be significantly reduced in CTX-implanted brains compared with Sham (Media) and Fibroblast treatment (Figure 5A), although we observed small portions of grafted CTX cells turned into GFAP-positive cells (Supporting Information Figure S2). Second, we examined the microglial response. Brain sections from all three treatment groups were subject to IBA-1 immunohistochemistry and it was significantly reduced in the CTX-implanted brains compared with Sham (Media) and Fibroblast treatment (Supporting Information

**FIGURE 3**  CTX cells implanted in the cortex can differentiate into cortical neurons. Colocalization (yellow) of hNu and Trb1 demonstrates neuronal differentiation of CTX cells in the cortex 13 weeks after transplantation (arrows). Scale bar = 50 μm

**FIGURE 4**  CTX cells can establish striato-pallidal connection in the quinolinic acid (QA)-lesioned striatum. Colocalization (yellow) of Fluoro-Gold (FG) and human nuclei in CTX cells (arrows) within the stratum suggests some restoration of local circuitry. Scale bar = 50 μm
Figure S3). Finally, we quantified the macrophage response to the lesion and graft. Brain sections from all three treatment groups were subject to double-label immunohistochemistry using a cocktail of anti-ED1 and anti-iNOS or anti-ED1 and anti-CD206 antibodies to detect pro- and anti-inflammatory macrophage phenotypes, respectively. Quantification of these cell types in the lesioned striatum showed a significant reduction and increase in iNOS/ED1 (M1 proinflammatory) and CD206/ED1 (M2 anti-inflammatory) cells, respectively, compared with the Sham (media) and Fibroblasts groups (Figure 5B,C).

3.5 | Increased endogenous neurogenesis following transplantation of CTX cells

Brain sections collected from animals (ie, all three treatment groups) previously administered with BrdU were subject to double-label immunohistochemistry with anti-BrdU and anti-DCX antibodies. Quantification of BrdU+, DCX+, and DCX+/BrdU+ cells showed an increase in all these phenotypes in the SVZ of CTX-implanted brains compared with those of the Sham (media) and Fibroblast groups (Figure 6).

3.6 | Increased endogenous angiogenesis following transplantation of CTX cells

Brain sections from all treatment groups were subject to RECA-1 immunohistochemistry to examine vascularization. RECA-1 staining, quantified by image analysis, and counts of branch point and microvessels in the lesioned striatum were shown to be significantly increased in the CTX-implanted brains compared with the Sham (Media) and Fibroblast treated brains (Figure 7).

4 | DISCUSSION

In this study, we explored the therapeutic effect of CTX, a conditionally immortalized GMP-manufactured human NSC, in the QA model of HD using various behavioral and IHC analyses. Injection of QA, an intrinsic neuroactive metabolite of the kynurenine pathway, can induce degeneration of striatal GABAergic projection neurons while preserving striatal afferents, which resembles the neuropathologic condition in HD patients. QA-lesioned rats is one of the most well-characterized HD models for motor and cognitive symptoms.

**FIGURE 5**  CTX cells decrease gliosis and proinflammatory responses in the quinolinic acid (QA)-lesioned striatum. A, GFAP staining was significantly reduced in CTX-implanted brains compared with Sham (Media) and Fibroblast (FB) injected brains (CTX vs Sham P = .004; CTX vs FB P = .014). Scale bar = 50 μm. B, CTX cells reduce a M1 proinflammatory phenotype of macrophage in the QA-lesioned striatum. The percentage of iNOS/ED1 was reduced in CTX treated brains compared with Sham (Media) and Fibroblast grafted brains (CTX vs Sham P < .001, CTX vs FB P = .017). C, CTX cells increase an M2 anti-inflammatory phenotype in the QA-lesioned striatum. CD206/ED1 increased in CTX treated brains compared with Sham (Media) and Fibroblast injected brains (CTX vs Sham P < .001, CTX vs FB P < .001). Scale bar = 50 μm
FIGURE 6  CTX cells promote neurogenesis in the quinolinic acid (QA)-lesioned brain. Compared with Sham (Media) and Fibroblast injected brains, the proportion of both BrdU and DCX stained cells was increased markedly in the SVZ of CTX treated brains (BrdU/DAPI CTX vs Sham \( P < .001 \), CTX vs FB \( P < .001 \); DCX/DAPI CTX vs Sham \( P < .001 \), CTX vs FB \( P = .002 \)). The percentage of DCX expressing cells in BrdU-positive cells in the SVZ was also significantly increased in CTX treated brains (DCX/BrdU CTX vs Sham \( P = .025 \), CTX vs FB \( P = .029 \)). Scale bar = 100 μm.

FIGURE 7  CTX cells promote angiogenesis in the quinolinic acid (QA)-lesioned brain. RECA-1 staining demonstrates that the number of branch points and microvessels was all significantly increased in CTX-implanted brains compared with Sham (Media) and Fibroblast injected brains (branch points \( P < .001 \) CTX vs Sham; \( P < .001 \) CTX vs FB; microvessels \( P < .001 \) CTX vs Sham; \( P < .001 \) CTX vs FB). Scale bar = 50 μm.
including decreased spontaneous locomotion, profound impairment in paw reaching test and place-learning deficit in the Morris water maze, and have been used as a useful model to evaluate the efficacy of stem cell transplantation in terms of behavioral and pathological changes.26

Rotarod, stepping, and staircase tests were employed to assess motor coordination, akinesia, and fine motor reaching skills, respectively, and the pre- and post-lesioning behavioral deficits following CTX cell transplantation were analyzed compared to those following sham and fibroblast transplantation. The effect of CTX transplantation was also evaluated in terms of cell survival, differentiation, and connectivity as well as their effects on innate regenerative processes such as angiogenesis and neurogenesis and the inflammatory response. As for the target sites for CTX transplantation, the cerebral cortex in addition to the striatum was selected because cortical cell loss can also contribute to motor symptoms, which has been ascribed primarily to the striatum in HD patients.27,28 At the same time, the in vivo potential of CTX cells to differentiate into the region-specific neurons can be evaluated through this approach.

Behaviorally, we found that the QA-lesioning-induced behavioral deficits were partially reversed between 8 and 12 weeks after CTX implantation (Figure 1). Although non-QA-lesioned animals would be useful as an intertrial test to demonstrate the behavior of “normal” rats, CTX-implanted rats performed significantly better on all three different behavioral tests employed at these time points, when compared with sham (media) and fibroblast transplants. This delay in benefits is in line with what has been reported previously with CTX transplantation in chronic stroke model.29 This suggests that the capability of CTX may be attributed to progressive replacement of injured neurons and/or modulation of the host environment to promote regenerative mechanisms rather than through some direct lesion modifying effect.

As shown from IHC analyses, CTX cells can survive, express BDNF, and differentiate into the region-specific neurons in the striatum (DARPP-32, GAD65/67) (Figure 2) and in the cortex (Tbr1, Figure 3) in vivo at 13 weeks after transplantation. The presence of FG within the surviving CTX also suggests that these cells can form local circuits (Figure 4). It will be very useful to perform electrophysiology in the future, to confirm the neuronal integration and action potentials of the transplanted cells. All these results suggest that CTX cells have a significant potential as a cell replacement therapy for HD.

Previous reports demonstrated that BDNF-overexpressing NSCs are neuroprotective in the MCAO model of stroke.30 Likewise, the current CTX-transplanted HD model also expressed BDNF, suggesting that production of BDNF from CTX provided neuroprotective effects in HD. This may also explain some of the other changes we observed in the host brain following transplantation.

In neurodegenerative diseases, including HD, the astrocytic and microglial responses are thought to have a role in driving the disease process.31 In the present study, we found that CTX cells can modulate a broad spectrum of host cellular responses in a positive way to promote regeneration and repair. In particular, both astrocyte and microglial responses were significantly reduced in brains implanted with CTX. Astrocytes are known to form a glial scar to isolate injured tissue for protecting neurons from contact-induced apoptosis, and microglia clean up the site of injury by phagocytosis of cellular debris and dead neurons.32,33 We found that CTX transplantation can lead to a significant decrease of glial scar formation (Figure 5A). Interestingly, we also observed small portions of grafted CTX cells turned into GFAP-positive astroglia cells (Supporting Information Figure S2), suggesting a contribution of graft-derived glial cells to the rescue of HD phenotypes.34 CTX transplantation was also shown to modulate macrophages in the lesioned striatum. Macrophages can change their characteristics in response to environmental changes, which result in a dual role in the response to injury.35 The phagocytic M1 phenotype functions like microglia to remove the post-injury cellular debris, while the M2 type anti-inflammatory phenotype secretes a cocktail of anti-inflammatory mediators that promote wound repair. In the chronic inflammatory environment, the persistent M1 phenotype leads to increased secretion of proinflammatory mediators and enzymes that cause further tissue destruction and injury. Importantly, polarization of M1 to an M2 phenotype is a key event for the resolution of inflammation and the initiation of reparative mechanisms.36 We found that CTX led to an M1 to M2 polarization as demonstrated by a predominance of a CD206 M2 phenotype and a reduction in the inflammatory iNOS M1 phenotype in the lesioned striatum implanted with CTX (Figure 5B,C). Taken together, it is evident that CTX implantation can not only replace lost cells and make connection but also has the ability to reduce the responses of several cell types involved in neuroinflammation.

Finally, we were able to show that CTX implantation promotes other reparative mechanisms in the brains of HD model. IHC staining using BrdU combined with DCX (a marker of migrating neuroblasts) showed a significant increase in the subventricular zone (SVZ) of CTX-transplanted brains (Figure 6), which is in line with a previous report showing that there is a significant increase in DCX/Ki67 neuroblasts in CTX-implanted MCAO brains.37 In addition, we found that blood vessel formation is significantly increased, as seen with Reca1 staining, in CTX-transplanted brains (Figure 7), again in line with what is seen with these cells in stroke models.38

5 | CONCLUSION

We have shown that CTX implantation is an effective treatment in the QA model of HD and works through multiple mechanisms, including cell replacement. Transplantation of CTX cells improved lesion-associated behavioral deficits on the rotarod, stepping, and staircase tests. Characterization of transplanted CTX demonstrated that they could undergo region-specific differentiation in the striatum and the cortex and establishment of striato-pallidal connections with the host tissue. Moreover, CTX transplantation reduced the local host inflammatory responses and promoted regenerative mechanisms such as angiogenesis and neurogenesis. Although additional analysis using transgenic HD mouse models will be useful, given all these current results and the fact that the cell has already been subject of clinical trials in stroke, CTX offers great potential as treatment for patients with HD.
ACKNOWLEDGMENTS
This research was supported by the National Research Foundation of Korea (NRF-2017M3A9B4061407), Republic of Korea, and by the internal funding of ReNeuron, United Kingdom, and iPS Bio, Inc, Republic of Korea.

CONFLICT OF INTEREST
L.S., C.H., R.C., and J.D.S. are employees of ReNeuron. J.S. is the founder and CEO of iPS Bio, Inc. The other authors declared no potential conflicts of interest.

AUTHOR CONTRIBUTIONS
J.S.: conceived the study, designed the experiments, provided funding for the work, wrote the manuscript, supervised the entire work, and approved the final submission of manuscript; J.D.S.: conceived the study, designed the experiments, provided funding for the work, and wrote the manuscript; R.C.: conceived the study, designed the experiments, analyzed the results, and contributed to writing of the manuscript; Y.Y., I.J., H.S.K., S.J., J.E.N., H.J.P.: performed the experiment; L.S., C.H., R.C., and J.D.S. are employees of ReNeuron. J.S. is the founder and CEO of iPS Bio, Inc. The other authors declared no potential conflicts of interest.

DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available from the corresponding author upon reasonable request.

ORCID
Jihwan Song https://orcid.org/0000-0002-6597-8208

REFERENCES
1. Pringsheim T, Wiltshire K, Day L, Dykeman J, Steeves T, Jette N. The incidence and prevalence of Huntington’s disease: a systematic review and meta-analysis. Mov Disord. 2012;27:1083-1091.
2. Connor B. Concise review: the use of stem cells for understanding and treating Huntington’s disease. Stem Cells. 2018;36:146-160.
3. Dunnett SB, Rossier AE. Cell therapy in Huntington’s disease. NeuroRx. 2004;1:394-405.
4. Kim HS, Song J. Cell therapy in Huntington’s disease. In: Demirer T, ed. Progress in Stem Cell Transplantation; 2015:77-109. https://www.intechopen.com/books/progress-in-stem-cell-transplantation/cell-therapy-in-huntington-s-disease.
5. Lee ST, Chu K, Park JE, et al. Intravenous administration of human neural stem cells induces functional recovery in Huntington’s disease rat model. Neurosci Res. 2005;52:243-249.
6. Ryu JK, Kim J, Cho SJ, et al. Proactive transplantation of human neural stem cells prevents degeneration of striatal neurons in a rat model of Huntington disease. Neurobiol Dis. 2004;16:68-77.
7. Johann V, Schiefer J, Sass C, et al. Time of transplantation and cell preparation determine neural stem cell survival in a mouse model of Huntington’s disease. Exp Brain Res. 2007;177:458-470.
8. Al-Gharaibeh A, Culver R, Stewart AN, et al. Induced pluripotent stem cell-derived neural stem cell transplantsions reduced behavioral deficits and ameliorated neuropathological changes in YAC128 mouse model of Huntington’s disease. Front Neurosci. 2017;11:628.
9. Stroemer P, Patel S, Hope A, Oliveira C, Pollock K, Sinden J. The neural stem cell line CTX0E03 promotes behavioral recovery and endogenous neurogenesis after experimental stroke in a dose-dependent fashion. Neurorehabil Neural Repair. 2009;23:895-909.
10. Kalladka D, Sinden J, Pollock K, et al. Human neural stem cells in patients with chronic ischaemic stroke (PISCES): a phase 1, first-in-man study. Lancet. 2016;388:787-796.
11. Hicks C, Stevanato L, Stroemer RP, Tang E, Richardson S, Sinden JD. In vivo and in vitro characterization of the angiogenic effect of CTX0E03 human neural stem cells. Cell Transplant. 2013;22:1541-1552.
12. Sinden JD, Hicks C, Stroemer P, Vishnubhatla I, Corteling R. Human neural stem cell therapy for chronic ischemic stroke: charting Progress from laboratory to patients. Stem Cells Dev. 2017;26:933-947.
13. Lelos MJ, Dunnett SB. Generating Excitotoxic lesion models of Huntington’s disease. Methods Mol Biol. 1780;2018:209-220.
14. Pollock K, Stroemer P, Patel S, et al. A conditionally immortal clonal stem cell line from human cortical neuroepithelium for the treatment of ischemic stroke. Exp Neurol. 2006;199:143-155.
15. Conte-Perales L, Barroso-Chinea P, Rio AJ, et al. Neuroanatomical tracing combined with in situ hybridization: analysis of gene expression patterns within brain circuits of interest. J Neurosci Methods. 2010;194:28-33.
16. Wojtowicz JM, Kee N. BrdU assay for neurogenesis in rodents. Nat Protoc. 2006;1:1399-1405.
17. Hanna J, Wernig M, Markoulaki S, et al. Treatment of sickle cell anemia mouse model with iPSCs generated from autologous skin. Science. 2007;318:1920-1923.
18. Jeon I, Lee N, Li JY, et al. Neuronal properties, in vivo effects, and pathology of a Huntington’s disease patient-derived induced pluripotent stem cells. Stem Cells. 2012;30:2054-2062.
19. Chang D-J, Lee N, Choi C, et al. Therapeutic effect of BDNF-over-expressing human neural stem cells (HB1. F3. BDNF) in a rodent model of middle cerebral artery occlusion. Cell Transplant. 2013;22:1441-1452.
20. Takahashi K, Tanabe K, Oshuku M, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007;131:861-872.
21. Schwarzer R, Whetsell WW Jr, Mangano RM. Quinolinic acid: an endogenous metabolite that produces axon-sparing lesions in rat brain. Science. 1983;219:316-318.
22. Beal MF, Ferrante RJ, Swartz KJ, Kowall NW. Chronic quinolinic acid lesions in rats closely resemble Huntington’s disease. J Neurosci. 1991;11:1649-1659.
23. Polopoli P, Pezzola A, Domenici MR, et al. Behavioral and electrophysiological correlates of the quinolinic acid rat model of Huntington’s disease. Brain Res Bull. 1994;35:329-335.
24. Francis L, Cruz R, Antunez I, et al. Establishing a rodent model of Huntington’s disease. J Comp Neurol. 2004;475:211-219.
25. Sanberg PR, Calderon SF, Giordano M, Tew JM, Norman AB. The quinolinic acid model of middle cerebral artery occlusion: a phase 1, first-in-human study. Brain Res Bull. 2009;23:1016-1021.
26. McBride JL, Behrstock SP, Chen EY, et al. Human neural stem cell transplants improve motor function in a rat model of Huntington’s disease. J Neurosci. 2004;24:105-106.
27. Rosas HD, Salat DH, Lee SY, et al. Cerebral cortex and the clinical expression of Huntington’s disease: complexity and heterogeneity. Brain. 2008;131:1057-1068.
28. Thu DC, Oorschot DE, Tippett LJ, et al. Cell loss in the motor and cingulate cortex correlates with symptomatology in Huntington’s disease. Brain. 2010;133:1094-1110.
29. Smith EJ, Stroemer RP, Gorenkova N, et al. Implantation site and lesion topology determine efficacy of a human neural stem cell line in a rat model of chronic stroke. *STEM CELLS*. 2012;30:785-796.

30. Crotti A, Glass CK. The choreography of neuroinflammation in Huntington’s disease. *Trends Immunol*. 2015;36:364-373.

31. Amor S, Peferoen LA, Vogel DY, et al. Inflammation in neurodegenerative diseases—an update. *Immunology*. 2014;142:151-166.

32. Neumann H, Kotter MR, Franklin RJ. Debris clearance by microglia: an essential link between degeneration and regeneration. *Brain*. 2009;132:288-295.

33. Loov C, Hillered L, Ebendal T, et al. Engulfing astrocytes protect neurons from contact-induced apoptosis following injury. *PLoS One*. 2012;7:e33090.

34. Benraiss A, Wang S, Herrlinger S, et al. Human glia can both induce and rescue aspects of disease phenotype in Huntington disease. *Nat Commun*. 2016;7:11758.

35. Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. *Nat Rev Immunol*. 2008;8:958-969.

36. Mills CD. M1 and M2 macrophages: oracles of health and disease. *Crit Rev Immunol*. 2012;32:463-488.

37. Hassani Z, O’Reilly J, Pearse Y, et al. Human neural progenitor cell engraftment increases neurogenesis and microglial recruitment in the brain of rats with stroke. *PLoS One*. 2012;7:e50444.

38. Reidling JC, Relano-Gines A, Holley SM, et al. Human neural stem cell transplantation rescues functional deficits in R6/2 and Q140 Huntington’s disease mice. *Stem Cell Rep*. 2018;10:58-72.

SUPPORTING INFORMATION
Additional supporting information may be found online in the Supporting Information section at the end of this article.

How to cite this article: Yoon Y, Kim HS, Jeon I, et al. Implantation of the clinical-grade human neural stem cell line, CTX0E03, rescues the behavioral and pathological deficits in the quinolinic acid-lesioned rodent model of Huntington’s disease. *Stem Cells*. 2020;38:936–947. https://doi.org/10.1002/stem.3191